Politics and GovernmentPolitics and Government
Sat, March 8, 2025
Fri, March 7, 2025

Judge rules against compounding group; Hims' shares fall


Published on 2025-03-07 10:40:58 - STAT
  Print publication without navigation

  • From STAT's Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making copies of Eli Lilly's obesity drug tirzepatide (sold under the brand names Mounjaro and Zepbound).

The article from STAT News, published on March 7, 2025, discusses several key developments in the biotech industry. It highlights Dr. Marty Makary's testimony at an FDA hearing, where he criticized the agency's handling of the Covid-19 vaccine approval process, suggesting it was rushed and lacked sufficient transparency. Additionally, shares of Hims & Hers Health Inc. surged after the company announced a new telehealth service aimed at providing mental health support. Nimbus Therapeutics received a significant investment to further develop its portfolio, particularly focusing on treatments for autoimmune diseases. Lastly, the article touches on the ongoing debate around the use of Ozempic for weight loss, with new data suggesting potential long-term benefits but also raising concerns about side effects and the drug's availability for diabetic patients.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/03/07/biotech-news-makary-fda-hearing-hims-shares-nimbus-ozempic-the-readout/ ]
Similar Politics and Government Articles